Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence
Tóm tắt
Từ khóa
Tài liệu tham khảo
Libby, 1995, Molecular bases of the acute coronary syndromes, Circulation, 91, 2844, 10.1161/01.CIR.91.11.2844
Fuster, 1992, The pathogenesis of coronary artery disease and the acute coronary syndromes (2), New Engl. J. Med., 326, 310, 10.1056/NEJM199201303260506
Henry, 1985, Atherosclerosis, calcium, and calcium antagonists, Circulation, 72, 456, 10.1161/01.CIR.72.3.456
van der Wal, 1994, Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology, Circulation, 89, 36, 10.1161/01.CIR.89.1.36
Davies, 1993, Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content, Br. Heart J., 69, 377, 10.1136/hrt.69.5.377
Libby, 1996, Macrophages and atherosclerotic plaque stability, Curr. Opin. Lipidol., 7, 330, 10.1097/00041433-199610000-00012
Dollery, 1995, Matrix metalloproteinases and cardiovascular disease, Circ. Res., 77, 863, 10.1161/01.RES.77.5.863
Brown, 1993, Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease, Circulation, 87, 1781, 10.1161/01.CIR.87.6.1781
Blankenhorn, 1994, Arterial imaging and atherosclerosis reversal, Arterioscler. Thromb. Vasc. Biol., 14, 177, 10.1161/01.ATV.14.2.177
Levine, 1995, Cholesterol reduction in cardiovascular disease: clinical benefits and possible mechanisms, New Engl. J. Med., 332, 512, 10.1056/NEJM199502233320807
Glagov, 1987, Compensatory enlargement of human atherosclerotic coronary arteries, New Engl. J. Med., 316, 1371, 10.1056/NEJM198705283162204
Davies, 1996, Stability and instability: two faces of coronary atherosclerosis, Circulation, 94, 2013, 10.1161/01.CIR.94.8.2013
Hsueh, 1992, Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus, Hypertension, 20, 253, 10.1161/01.HYP.20.2.253
Tesfamariam, 1991, Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C, J. Clin. Invest., 87, 1643, 10.1172/JCI115179
Henry, 1991, Antiperoxidative actions of calcium antagonists and atherogenesis, J. Cardiovasc. Pharmacol., 18, S6, 10.1097/00005344-199100181-00003
Fleckenstein, 1987, The role of calcium in the pathogenesis of experimental arteriosclerosis, Trends Pharmacol. Sci., 8, 496, 10.1016/0165-6147(87)90046-0
Waters, 1990, A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis, Circulation, 82, 1940, 10.1161/01.CIR.82.6.1940
Lichtlen, 1990, Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT), Lancet, 335, 1109, 10.1016/0140-6736(90)91121-P
Borhani, 1996, Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial, J. Am. Med. Assoc., 276, 785, 10.1001/jama.276.10.785
Henry, 1981, Suppression of atherosclerosis in cholesterol-fed rabbits treated with nifedipine, J. Clin. Invest., 68, 1366, 10.1172/JCI110384
Byington, 1997, Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events, Lancet, 350, 1075, 10.1016/S0140-6736(05)70455-4
Pitt, 2000, Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events, Circulation, 102, 1503, 10.1161/01.CIR.102.13.1503
Jorgensen, 2000, Restenosis and clinical outcomes in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES), J. Am. Coll. Cardiol., 35, 592, 10.1016/S0735-1097(99)00599-9
Mason, 1992, Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer, Mol. Pharmacol., 41, 315
Mason, 1992, An examination of the chemical and physical interactions of lipid soluble drugs with membranes in the heart and brain
Mason, 1999, Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine, J. Mol. Cell. Cardiol., 31, 275, 10.1006/jmcc.1998.0867
Herbette, 1994, The molecular basis for lacidipine's unique pharmacokinetics: optimal hydrophobicity results in membrane interactions that may facilitate the treatment of atherosclerosis, J. Cardiovasc. Pharmacol., 23, S16, 10.1097/00005344-199423005-00005
Herbette, 1998, Lercanidipine: short plasma half life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties, Blood Pressure, 7, 10, 10.1080/080370598438998
Mason, 1989, Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes, Mol. Pharmacol., 36, 634
Bauerle, 1991, Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes. Binding equilibrium, binding enthalpy, and membrane location, Biochemistry, 30, 7203, 10.1021/bi00243a023
Mason, 1998, Cytoprotective properties of a long-acting calcium channel blocker: new mechanism of action, Am. J. Hypertension, 11, 245A, 10.1016/S0895-7061(97)91649-6
Tulenko, 1997, Cholesterol, calcium and atherosclerosis: Is there a role for calcium channel blockers in atheroprotection?, Int. J. Cardiol., 62, 55S, 10.1016/S0167-5273(97)00242-8
Tulenko, 1995, Actions of the charged dihydropyridine amlodipine in a cell culture model of dietary atherosclerosis, J. Cardiovasc. Pharmacol., 26, S11
Kramsch, 1997, Limits of lipid-lowering therapy: the potential benefits of amlodipine as an antiatherosclerotic agent, Int. J. Cardiol., 62, S119, 10.1016/S0167-5273(97)00249-0
Zhang X, Hintze TH. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent, 1998.
Mason, 1993, Membrane interaction of calcium channel antagonists modulated by cholesterol. Implications for drug activity, Biochem. Pharmacol., 45, 2173, 10.1016/0006-2952(93)90186-Z
Kass, 1989, Influence of pH on calcium channel block by amlodipine, a charged dihydropyridine compound. Implications for location of the dihydropyridine receptor, J. Gen. Physiol., 93, 1109, 10.1085/jgp.93.6.1109
Kramsch, 1995, Limits of lipid-lowering therapy: the benefits of amlodipine as an anti-atherosclerotic agent, J. Hum. Hypertension, 9, S3
Chen, 1997, Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine, J. Am. Coll. Cardiol., 30, 569, 10.1016/S0735-1097(97)00158-7
Mak, 1992, Antioxidant properties of active and inactive isomers of nicardipine in cardiac membranes, endothelial cells, and perfused rat hearts, Coron. Artery Dis., 3, 1095, 10.1097/00019501-199211000-00013
Mak, 1992, Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells: correlation of protection with preservation of glutathione levels, Circ. Res., 70, 1099, 10.1161/01.RES.70.6.1099
Mak, 1990, Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation, Circ. Res., 66, 1449, 10.1161/01.RES.66.5.1449
Leonard, 1991, Interactions of cholesterol with the membrane lipid matrix: a solid state NMR approach, Biochimie, 73, 1295, 10.1016/0300-9084(91)90092-F
Yeagle, 1985, Cholesterol and the cell membrane, Biochim. Biophys. Acta, 822, 267, 10.1016/0304-4157(85)90011-5
Chen, 1991, Structural, compositional and functional alterations of arterial smooth muscle plasma membranes in atherosclerosis, FASEB J., 5, A531
McIntosh, 1978, The effect of cholesterol on the structure of phosphatidylcholine bilayers, Biochim. Biophys. Acta, 513, 43, 10.1016/0005-2736(78)90110-4
Franks, 1976, Structural analysis of hydrated egg lecithin and cholesterol bilayers. I. X-ray diffraction, J. Mol. Biol., 100, 345, 10.1016/S0022-2836(76)80067-8
Tulenko, 1998, Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis, J. Lipid Res., 39, 947, 10.1016/S0022-2275(20)33861-X
Kellner-Weibel, 1999, Cystallization of free cholesterol in model macrophage foam cells, Arterioscler, Thromb. Vasc. Biol., 19, 1891, 10.1161/01.ATV.19.8.1891
Mason, 1995, Differential effect of cholesterol on charged versus uncharged 1,4-dihydropyridine calcium channel antagonists: a biophysical approach, Cardiovasc. Drugs Ther., 9, 45, 10.1007/BF00878572
McMurray, 1992, Amlodipine exerts a potent antimigrational effect on aortic smooth muscle cells in culture, J. Cardiovasc. Pharmacol., 20, S54
Mason, 1999, Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells, J. Neurochem., 72, 1448, 10.1046/j.1471-4159.1999.721448.x
Eickelberg, 1997, Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection, Int. J. Cardiol., 62, S31, 10.1016/S0167-5273(97)00239-8
Galis, 1994, Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaque, J. Clin. Invest., 94, 2493, 10.1172/JCI117619
Roth, 1996, Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix, Proc. Natl. Acad. Sci. USA, 93, 5478, 10.1073/pnas.93.11.5478
Ikeda, 2000, Amlodipine inhibits expression of matrix metalloproteinase-1 and its inhibitor in human vascular endothelial cells, J. Cardiovasc. Pharmacol., 35, 887, 10.1097/00005344-200006000-00009
Mason, 1999, Calcium antagonists and cardiovascular risk in diabetes, Diabetes Care, 22, 1206, 10.2337/diacare.22.7.1206
Fuller, 1991, Epidemiology of hypertension in diabetic patients and implications for treatment, Diabetes Care, 14, 8, 10.2337/diacare.14.4.8
Turner, 1998, Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23), Br. Med. J., 316, 823, 10.1136/bmj.316.7134.823
1997, The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI), Arch. Intern. Med., 157, 2413, 10.1001/archinte.157.21.2413
Estacio, 1998, The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension, New Engl. J. Med., 338, 645, 10.1056/NEJM199803053381003
Byington, 1998, Isradipine in prediabetc hypertensive subjects, Diabetes Care, 21, 2103, 10.2337/diacare.21.12.2103
Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6
Parving, 1998, Calcium antagonists and cardiovascular risk in diabetes, Am. J. Cardiol., 82, 42R, 10.1016/S0002-9149(98)00758-9
Tuomilehto, 1999, Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension, New Engl. J. Med., 340, 677, 10.1056/NEJM199903043400902